Key Takeaways

• BPC-157 and TB-500 have never been studied together as a pair. The whole protocol rests on preclinical models and a few small case series.
• BPC-157 runs roughly 200-400 µg daily. TB-500 sits around 2-5 IU, or 0.5-1 mg.
• BPC-157 clears in under 30 minutes, which is why you split it into 2-3 doses a day.
• TB-500’s 24-48 hour half-life means one daily shot does the job.
• BPC-157’s oral bioavailability is under 1%, so subcutaneous injection is the only route that makes sense.
• Vial IU markings aren’t standardized. Start from 1 IU TB-500 ≈ 0.2 mg, then adjust for your vendor’s purity.
• The huge half-life gap between these two peptides drives every dosing decision in the stack.

The raw numbers before you split anything

A wolverine stack daily dosage works off two very different peptides with two very different half-lives. Get the math wrong and you’ll either waste product or under-dose an injury that actually needed the exposure.

Honest starting point: nobody has a validated human dose-response curve for this combination. It’s never been formally researched as a pair. The evidence sits in preclinical models plus a handful of small case series. So treat every number below as an experimental protocol anchored to pharmacokinetics, not proven clinical medicine.

The basic specs on both peptides

BPC-157: a 2.5 kDa synthetic pentadecapeptide. Oral bioavailability under 1%, so subcutaneous injection is the practical route. Working range is roughly 200-400 µg per day.

TB-500: a larger 5 kDa fragment of thymosin beta-4, dosed around 2-5 IU per day (roughly 0.5-1 mg). Half-life stretches to 24-48 hours.

That half-life gap is the whole reason the stack splits the way it does. BPC-157 clears fast, with a half-life under 30 minutes, hepatic metabolism and renal clearance. That short window is exactly why you dose it 2-3 times daily to keep tissue exposure steady. TB-500’s long tail rides on a single daily shot.

Converting IU to milligrams

Use 1 IU TB-500 ≈ 0.2 mg as your baseline, then adjust for vendor purity. IU markings on peptide vials aren’t standardized, so a reconstitution that assumes 0.2 mg per IU can be off if your batch runs dirtier or cleaner than the label claims.

Take a 70 kg adult targeting tendon repair. You’d aim for around 300 µg BPC-157 split into two 150 µg shots, plus one daily TB-500 dose near 4 IU (about 0.8 mg). Insulin syringes marked in units make small-volume draws readable. Digital dose-trackers help you log the split without guessing.

Dose-frequency and cost matrix

General reference framework, not a guarantee. Timelines assume consistent dosing.

Injury Type	Daily BPC-157 (mg)	Daily TB-500 (IU)	Split Ratio (BPC/TB)	Timing & ~Weekly Cost
Minor strain	0.25	2	2:1	AM + PM BPC, AM TB · ~$35
Tendon repair	0.30	4	3:2	2-3× BPC, 1× TB · ~$55
Ligament/joint	0.40	5	2:1	3× BPC, 1× TB · ~$70

Where biomarkers come in

Blood-panel data lets you tune the split instead of guessing. Elevated CRP points toward front-loading the anti-inflammatory work. IGF-1 context helps you judge repair capacity. At BiohackNow, our team reviews blood work in depth to build personalized peptide protocols under medical supervision.

One caveat, stated plainly: skip this stack entirely if you compete under WADA rules. Both peptides are banned in sport, and no biomarker split changes that.

Timing: pre-workout, post-workout, and rest days

Dose BPC-157 before training to prime tissue. Dose TB-500 after to support remodeling. Drop to a single maintenance shot on rest days. The rest of this section builds a real weekly calendar around that logic, and shows how your inflammatory markers should nudge the timing.

Why dose BPC-157 before you train

Dosing BPC-157 before exercise uses the acute mechanical stress of training to your advantage. During muscle contraction, local growth factors and angiogenic signals spike naturally. Introducing the peptide in that window aims to work alongside those pathways, particularly VEGFR2 upregulation, to concentrate the healing response at the active injury site.

You want the peptide active during and right after micro-trauma, when angiogenic signaling matters most. A shot 20 to 30 minutes before your session puts peak tissue exposure where the damage happens. This is also the mechanistic case for splitting BPC-157 across the day. One morning shot won’t cover an evening session.

If your inflammatory markers run high, weight the pre-training dose a little heavier. Your body is already primed for repair signaling, so that’s the window to feed it.

When to put TB-500 in

TB-500 is the post-workout peptide. Its longer signaling profile suits the remodeling phase, so it goes in within 30 to 60 minutes after training. You’re not chasing a fast peak. You’re topping up a slow, sustained repair process.

Because it lingers, you don’t need it twice a day. Once post-session, on training days, keeps remodeling signals live. On heavy weeks, keep it consistent. On deload weeks, hold TB-500 steady but pull back the BPC-157 pre-dose, since there’s less micro-trauma to prime for.

What a 7-day split looks like

A sample week for a mixed-modal athlete running and lifting. Adjust volumes to your injury severity, not this template.

• Monday (lift): BPC-157 pre-lift, TB-500 post-lift
• Tuesday (run): BPC-157 pre-run, TB-500 post-run
• Wednesday (rest): single BPC-157 maintenance dose, morning
• Thursday (lift): BPC-157 pre-lift, TB-500 post-lift
• Friday (run): BPC-157 pre-run, TB-500 post-run
• Saturday (rest): single BPC-157 maintenance dose, morning
• Sunday (rest): single BPC-157 maintenance dose, morning

Rest-day dosing keeps baseline signaling alive without overstimulation. One BPC-157 shot maintains tissue exposure between hard sessions. TB-500 sits out entirely on rest days.

Chronobiology and shift-work adjustments

Line up injections with your natural cortisol rise, usually the first hour after waking. That morning window tends to support better uptake for the maintenance dose. Anchor timing to YOUR wake cycle, not the clock.

Night-shift workers and jet-lagged travelers should shift the whole schedule to their subjective morning. Wake at 6 PM? That’s your cortisol peak. Dose accordingly.

One practical fix: set repeating reminders tied to your training log so pre- and post-shots don’t slip. A structured routine is how you actually hit these timing windows week after week, which is what lets the two pharmacokinetic profiles work in tandem.

Injection sites and technique

Where you inject changes how each peptide behaves. BPC-157 goes subcutaneous, near the injury when you can, using the fat layer for slow, local release. TB-500 wants intramuscular placement for deeper penetration and better systemic distribution. Matching route to peptide is the second half of getting this stack to actually work.

The injury-severity logic from earlier carries straight into technique. A high-inflammation ACL sprain driving a heavier TB-500 split needs deep IM delivery into large muscle. A nagging tennis elbow on a light BPC-157 dose wants a shallow shot placed as close to the tendon as you can safely reach. Route follows the biomarker-driven decision, not habit.

Where to inject each one

BPC-157 (subcutaneous): pinch the skin and inject into the fat layer at a 4-5 mm depth. Best sites are the abdomen (about 2 inches from the umbilicus), the lateral thigh, and the upper arm. For localized injuries, place the shot near the damaged tissue when the site allows it.

TB-500 (intramuscular): aim for larger muscle bellies. The deltoid, vastus lateralis, and gluteus medius hold volume well and tolerate repeat dosing. IM depth gives the peptide a richer capillary bed, which suits its longer half-life and whole-body remodeling role.

Use a site-rotation matrix to protect your tissue. Map your body into left and right quadrants for each region, then cycle so no single spot gets hit twice in the same week. Rotation is how you avoid lipohypertrophy and scar tissue that blunts absorption over a multi-week protocol.

Making the injection painless

Painless injections come down to sharp, thin needles and a relaxed technique. Use a 31 to 33 gauge needle for subcutaneous BPC-157 shots. The thinner the gauge, the less you feel it. And slow injection speed matters more than most people expect.

Warm the vial in your hand for a minute before drawing. Cold peptide solution stings more going in. A dab of topical lidocaine on the site ten minutes ahead handles the rest for needle-shy users.

Same checklist, every time:

1. Swab the site with alcohol and let it dry fully. Wet alcohol dragged under the skin is what actually burns.
2. Aspiration test (optional for TB-500): pull back slightly on IM shots to confirm you’re not in a vessel. Skip it for the tiny subcutaneous BPC-157 volumes.
3. Inject slowly. Push over 5 to 10 seconds, not a fast jab. Slow delivery reduces tissue pressure and bruising.

If you’ve never self-administered, get initial instruction from a qualified provider to nail depth and sterile technique.

When to skip self-injection entirely

Skip it for intra-articular injections and any high-dose scenario. Placing a needle inside a joint capsule carries real infection and cartilage risk. This is not a technique to teach yourself from a video.

If your biomarker profile points to aggressive dosing for a severe tear, get a clinician to handle the deep or joint-adjacent work. For routine subcutaneous maintenance shots, self-injection is genuinely straightforward once you’ve done a few.

Tracking healing: biomarkers, milestones, adjustments

You can’t dose this stack blind. You need baseline numbers, weekly checkpoints, and a re-check that tells you whether to push the split harder or start backing off. That’s the whole point of a biomarker-driven protocol: the labs, not your gut, decide the next move.

Objective biomarkers are what move these experimental protocols from speculative schedules to responsive, data-driven frameworks.

Baseline labs to pull before day one

Draw blood before your first injection. You want a fixed reference point for every adjustment that follows.

A useful baseline panel covers:

• CRP and ESR: your inflammatory load. High readings on an acute injury justify a heavier TB-500 lean early.
• IGF-1: a proxy for anabolic tissue-repair capacity. Low IGF-1 changes what you can expect from remodeling.
• Collagen type I & III ratio: tendon and ligament remodeling skews toward type III early, then matures to type I. Watching that shift tells you whether tissue is actually maturing or stalling.

Log these alongside a pain VAS score (0 to 10), goniometer range-of-motion, and strength as a percent of your uninjured baseline. Numbers you can’t measure are numbers you can’t adjust against.

Weekly checkpoints and the day-14 re-check

Every seven days, re-score pain, ROM, and strength. These three functional metrics move faster than labs and catch plateaus early.

Day 14 is your decision fork. Re-pull CRP, ESR, and IGF-1. If inflammation has dropped and function is climbing, you’re on track. Hold the split. If CRP stays elevated and ROM hasn’t budged, that’s your signal to escalate the remodeling side.

The rough adjustment algorithm:

1. Function improving + inflammation falling → hold current split, start planning the taper.
2. Function flat + inflammation falling → increase TB-500, hold BPC-157.
3. Function flat + inflammation still high → hold TB-500, recheck injection site and technique before touching the dose.
4. Function regressing → stop and reassess the injury itself. Peptides don’t fix a missed structural diagnosis.

A worked example of pattern 2: an athlete plateaus at day 21, pain down but strength stuck at 70% of baseline. TB-500 goes from 2 IU to 3 IU while BPC-157 stays put. Re-check function the following week before touching it again.

When to stop versus shift to maintenance

Discontinue when function returns to baseline and inflammatory markers normalize. Full healing looks like pain VAS at or near zero, ROM matched to the uninjured side, and strength back to 95% or better.

Chronic or degenerative injuries are a different animal. Some tendinopathies never hit that clean endpoint, and a low maintenance dose may make sense. Don’t run open-ended dosing on a resolved acute strain. There’s no evidence supporting indefinite exposure once the tissue is repaired.

Track all of it in one place. Logging labs, VAS scores, and functional metrics consistently is what turns the day-14 fork into a decision instead of a guess. Our personalized protocols at BiohackNow are built around this kind of data-driven monitoring under medical supervision. More on our protocol thinking lives on our blog.

Safety, legal status, and quality assurance

Every version of this stack needs a hard ceiling and a plan for when something goes wrong. The peptides sit in a legal gray zone, purity varies wildly between suppliers, and the human safety data is thin. Get these fundamentals right before you touch a needle.

Setting strict boundaries matters most with compounds that lack large-scale clinical validation. Stick to conservative exposure limits and consult a qualified physician rather than running on self-experimentation alone.

Side effects to watch, and the weekly limits

Most reported reactions are mild and local: erythema at the injection site, transient fatigue in the hours after a dose, and rare hypersensitivity. If redness spreads or you feel systemic flu-like symptoms, stop and hold until you’re clear.

Commonly cited conservative weekly ceilings, aligned to the injury-severity splits from earlier:

• BPC-157: keep total weekly exposure at or under 2 mg/week. A tendon or ligament case (Achilles, rotator cuff) at 300 µg/day split 2-2 stays well inside this. A muscle strain at 250 µg/day (3-1 split) and a cartilage case at 200 µg/day (2-2) sit lower still.
• TB-500: some references suggest capping at ≤10 IU/week. Tendon work runs 3 IU nightly, muscle strain 2 IU, and cartilage cases up to 4 IU with one dose placed intra-articular under a clinician’s hands. None of these approach the ceiling.

These caps aren’t validated. They’re a safety buffer, which is why higher inflammatory or genetic risk markers should push you toward the low end of each range, never past it.

Why it’s “research-only,” and what that means for you

Neither peptide has completed FDA approval for any therapeutic indication. That classifies these substances strictly for laboratory research, which means standard health insurance won’t cover their cost, administration, or any medical complication tied to them.

Legal reality: In the US, these sell as research compounds, not therapeutics. The EU treats unlicensed peptides similarly, and several Asian markets restrict import outright. You carry the full liability yourself.

And if you’re drug-tested, know that both compounds are actively screened for. Detection can bring severe professional and competitive penalties.

Verifying purity before you inject

Never inject a peptide without a certificate of analysis and a matching HPLC chromatogram. The CoA should show purity, usually above 98%, plus mass-spec confirmation of the correct sequence. A clean chromatogram is a single sharp peak, not a cluster.

Demand third-party testing tied to the specific batch number on your vial, cold-chain handling in transit, and traceability back to synthesis. If a supplier can’t produce batch-linked documents, walk away.

One honest caveat on the evidence you’re staking this on: a 2019-2020 review of 17 knee-pain patients saw 11 of 12 report significant improvement from intra-articular BPC-157. Impressive on paper. But it’s an uncontrolled case series with real methodological flaws, so treat it as a reason to test carefully, not proof of safety.

For adverse events, log the date, dose, site, and reaction, then contact a licensed provider before your next shot. A structured report protects your next decision far more than guesswork.

---

Frequently Asked Questions

1. Can I mix BPC-157 and TB-500 in the same syringe to save time?

No. Combining different peptide structures in a single syringe can compromise their chemical stability and lead to premature degradation. Furthermore, because they target different tissue depths and follow distinct administration schedules, they must be drawn and injected separately to preserve their individual pharmacokinetic profiles.

2. What needle gauge and depth should I use for each peptide?

Subcutaneous injections typically utilize short, ultra-fine needles (such as 31G to 33G, 5/16 inch) to easily access the adipose layer. Intramuscular injections require slightly longer needles (such as 25G to 27G, 1/2 to 1 inch depending on body composition) to safely bypass subcutaneous fat and deposit the solution directly into well-vascularized muscle tissue.

3. How do I adjust dosing if I work night shifts?

Shift your administration schedule so that the primary daily dose occurs immediately upon waking, regardless of the actual hour. This aligns the exogenous peptides with your body’s natural diurnal hormone spikes, ensuring that metabolic activity and tissue uptake remain synchronized with your active hours.

4. What should I do if I hit a plateau at day 21?

A plateau at the three-week mark warrants a comprehensive review of your functional metrics and inflammatory markers. If systemic inflammation has resolved but functional recovery has stalled, consider adjusting the systemic remodeling component of your protocol or consulting a specialist to rule out mechanical issues like scar tissue or structural tears.

5. How do I verify a peptide supplier is legitimate before injecting?

Look for vendors that provide transparent, batch-specific documentation rather than generic, outdated reports. Legitimate suppliers will readily share independent, third-party laboratory verifications and maintain strict quality control standards, including cold-chain shipping options to prevent peptide degradation during transit.

6. Is this stack safe if I compete in drug-tested sports?

Absolutely not. Anti-doping agencies utilize highly sensitive assays capable of detecting these compounds and their metabolites even at minute thresholds. Under the principle of strict liability, athletes are solely responsible for any prohibited substances found in their samples, making the use of these peptides an automatic violation.

7. When should I stop dosing versus switch to a maintenance dose?

Transitioning off the stack prevents potential receptor desensitization and allows your endogenous healing mechanisms to resume primary control. Once objective functional tests show that tissue strength and mobility have fully recovered, tapering off the compounds is recommended to avoid unnecessary systemic exposure.